P2RY12 and peripheral arterial disease: Meta‐analyses in patients with established atherosclerosis including CAD, ischemic stroke, or peripheral artery disease, have indicated that P2Y12 inhibitor monotherapy lowers ischemic risk, particularly MI, without increasing severe bleeding [10, 11].